Switch to Aflibercept in the Treatment of Neovascular AMD: Long-Term Results
| Autor: | Pedro Neves Cardoso, Ana Fernanda Pinheiro, Jorge Meira, Ana Catarina Pedrosa, Manuel S. Falcão, João Pinheiro-Costa, Fernando Falcão-Reis, Ângela M. Carneiro |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: | |
| Zdroj: | Journal of Ophthalmology, Vol 2017 (2017) |
| Druh dokumentu: | article |
| ISSN: | 2090-004X 2090-0058 |
| DOI: | 10.1155/2017/6835782 |
| Popis: | Purpose. To report the long-term clinical outcomes after switching from intravitreal bevacizumab or ranibizumab to aflibercept therapy in eyes with AMD. Methods. Retrospective analysis of changes in BCVA, SD-OCT image, and frequency of injections after 1, 2, and 3 years of follow-up. Results. 164 eyes were analyzed, 101 eyes switched from bevacizumab (group 1) and 63 from ranibizumab (group 2). One year after the switch, there was an overall nonsignificant mean decrease of 2 ETDRS letters in BCVA. Three years after, there was an overall mean decrease of 7 ETDRS letters, which was statistically significant. A significant improvement in the mean CRT was found at 1, 2, and 3 years. There was a significant decrease in the mean number of injections per year (7.8 to 6.5, p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|